ALPS Advisors’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $503K | Buy |
7,782
+1,790
| +30% | +$126K | ﹤0.01% | 813 |
|
|
2025
Q4 | $403K | Buy |
5,992
+66
| +1% | +$4.44K | ﹤0.01% | 889 |
|
|
2025
Q3 | $435K | Buy |
5,926
+170
| +3% | +$11.3K | ﹤0.01% | 857 |
|
|
2025
Q2 | $299K | Buy |
5,756
+70
| +1% | +$3.98K | ﹤0.01% | 935 |
|
|
2025
Q1 | $363K | Sell |
5,686
-1
| -0% | -$58 | ﹤0.01% | 711 |
|
|
2024
Q4 | $272K | Hold |
5,687
| – | – | ﹤0.01% | 946 |
|
|
2024
Q3 | $326K | Sell |
5,687
-2,701
| -32% | -$155K | ﹤0.01% | 931 |
|
|
2024
Q2 | $439K | Sell |
8,388
-45
| -0.5% | -$1.97K | ﹤0.01% | 608 |
|
|
2024
Q1 | $343K | Sell |
8,433
-81
| -1% | -$3.04K | ﹤0.01% | 861 |
|
|
2023
Q4 | $315K | Sell |
8,514
-486
| -5% | -$18.3K | ﹤0.01% | 829 |
|
|
2023
Q3 | $344K | Buy |
+9,000
| New | +$369K | ﹤0.01% | 677 |
|
|
2023
Q1 | – | Sell |
-7,638
| Closed | -$435K | – | 1071 |
|
|
2022
Q4 | $435K | Sell |
7,638
-31
| -0.4% | -$1.59K | ﹤0.01% | 631 |
|
|
2022
Q3 | $303K | Buy |
+7,669
| New | +$339K | ﹤0.01% | 768 |
|
|
2022
Q1 | – | Sell |
-8,959
| Closed | -$360K | – | 888 |
|
|
2021
Q4 | $360K | Buy |
8,959
+180
| +2% | +$6.72K | ﹤0.01% | 758 |
|
|
2021
Q3 | $357K | Buy |
+8,779
| New | +$367K | ﹤0.01% | 690 |
|
|
2019
Q4 | – | Sell |
-291,765
| Closed | -$4.53M | – | 835 |
|
|
2019
Q3 | $4.53M | Sell |
291,765
-11,592
| -4% | -$191K | 0.04% | 150 |
|
|
2019
Q2 | $5.21M | Sell |
303,357
-46,953
| -13% | -$758K | 0.04% | 151 |
|
|
2019
Q1 | $5.64M | Sell |
350,310
-10,698
| -3% | -$173K | 0.04% | 153 |
|
|
2018
Q4 | $5.28M | Buy |
361,008
+77,631
| +27% | +$1.24M | 0.04% | 147 |
|
|
2018
Q3 | $5.15M | Buy |
283,377
+53,811
| +23% | +$943K | 0.03% | 161 |
|
|
2018
Q2 | $3.87M | Buy |
229,566
+14,709
| +7% | +$278K | 0.03% | 189 |
|
|
2018
Q1 | $4.21M | Buy |
214,857
+57,109
| +36% | +$1.11M | 0.03% | 160 |
|
|
2017
Q4 | $3.2M | Buy |
157,748
+17,984
| +13% | +$331K | 0.02% | 162 |
|
|
2017
Q3 | $2.43M | Buy |
139,764
+13,556
| +11% | +$184K | 0.02% | 176 |
|
|
2017
Q2 | $1.62M | Buy |
126,208
+14,807
| +13% | +$198K | 0.01% | 197 |
|
|
2017
Q1 | $1.44M | Sell |
111,401
-13,037
| -10% | -$165K | 0.01% | 191 |
|
|
2016
Q4 | $1.23M | Sell |
124,438
-40,544
| -25% | -$444K | 0.01% | 201 |
|
|
2016
Q3 | $1.99M | Sell |
164,982
-16,371
| -9% | -$167K | 0.02% | 183 |
|
|
2016
Q2 | $1.56M | Buy |
181,353
+38,688
| +27% | +$382K | 0.01% | 187 |
|
|
2016
Q1 | $1.35M | Sell |
142,665
-25,974
| -15% | -$244K | 0.01% | 173 |
|
|
2015
Q4 | $2.92M | Sell |
168,639
-30,553
| -15% | -$487K | 0.03% | 152 |
|
|
2015
Q3 | $26.8K | Buy |
199,192
+72,873
| +58% | +$1.46M | 0.03% | 151 |
|
|
2015
Q2 | $2.85M | Buy |
126,319
+64,009
| +103% | +$1.13M | 0.02% | 145 |
|
|
2015
Q1 | $890K | Buy |
+62,310
| New | +$898K | 0.01% | 190 |
|
Other funds holding HALO
VCM
VPM
ALPS Advisors's HALO Position: Q1 2026 in Review
ALPS Advisors increased its Halozyme (HALO) stake by 30% in Q1 2026, buying an estimated $126K and bringing the position to 7,782 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #813.
ALPS Advisors first reported a position in HALO in Q1 2015 and has held it in 34 quarters since. The position peaked at $5.64M in Q1 2019. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.
- ALPS Advisors held 7,782 shares of Halozyme worth $503K as of Q1 2026.
- ALPS Advisors bought 1,790 Halozyme shares in Q1 2026, an estimated $126K.
- Halozyme made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #813 holding.
- ALPS Advisors first reported a position in Halozyme in Q1 2015 and has held it in 34 quarters since.
- ALPS Advisors's Halozyme position peaked at $5.64M in Q1 2019.
- 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.